Needham & Company LLC reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research report released on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $8.00 price target on the stock.
Separately, Oppenheimer restated an outperform rating and set a $9.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, March 21st.
Read Our Latest Stock Analysis on Trevi Therapeutics
Trevi Therapeutics Stock Performance
Shares of NASDAQ:TRVI traded down $0.25 during trading hours on Tuesday, hitting $2.88. 554,225 shares of the company's stock traded hands, compared to its average volume of 296,173. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The company's fifty day simple moving average is $2.70 and its two-hundred day simple moving average is $1.94. The company has a market cap of $198.60 million, a price-to-earnings ratio of -9.93 and a beta of 0.86.
Institutional Trading of Trevi Therapeutics
A number of hedge funds have recently bought and sold shares of TRVI. Vanguard Group Inc. lifted its stake in Trevi Therapeutics by 7.6% during the first quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after buying an additional 10,780 shares in the last quarter. State Street Corp purchased a new stake in Trevi Therapeutics during the first quarter valued at about $81,000. Virtu Financial LLC purchased a new stake in Trevi Therapeutics during the first quarter valued at about $44,000. FMR LLC purchased a new stake in Trevi Therapeutics during the second quarter valued at about $234,000. Finally, Northern Trust Corp lifted its stake in Trevi Therapeutics by 305.6% during the second quarter. Northern Trust Corp now owns 46,298 shares of the company's stock valued at $130,000 after buying an additional 34,884 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Stories
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
